Pazopanib Hydrochloride in Treating Patients With Advanced or Refractory Solid Tumors
Status:
Active, not recruiting
Trial end date:
1969-12-31
Target enrollment:
Participant gender:
Summary
This phase I trial studies the side effects and the best dose of pazopanib hydrochloride in
treating patients with solid tumors that has spread to other places in the body and usually
cannot be cured or controlled with treatment (advanced) or does not respond to treatment
(refractory). Pazopanib hydrochloride may prevent the growth of new blood vessels that tumors
need to grow. Studying samples of blood in the laboratory from patients receiving pazopanib
hydrochloride may help doctors learn more about the effects of the body on the drug. It may
also help doctors understand how well patients respond to treatment.